Holen Sie sich die Stockscreener-App
11.69
2.19%
0.25
Handel nachbörslich:
11.83
0.14
+1.20%
Schlusskurs vom Vortag:
$11.44
Offen:
$11.54
24-Stunden-Volumen:
789.18K
Relative Volume:
0.33
Marktkapitalisierung:
$828.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.81M
KGV:
-6.2181
EPS:
-1.88
Netto-Cashflow:
$74.30M
1W Leistung:
+4.10%
1M Leistung:
-7.37%
6M Leistung:
+173.77%
1J Leistung:
+28.18%
1-Tages-Spanne:
$11.45
$12.14
1-Wochen-Bereich:
$11.00
$12.14
52-Wochen-Spanne:
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
Firmenname
Omeros Corporation
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
11.69 | 811.10M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corporation Aktie (OMER) Neueste Nachrichten
Is Omeros Corporation stock positioned well for digital economyJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - mfd.ru
What risks investors should watch in Omeros Corporation stockWeekly Investment Report & Long-Term Safe Investment Plans - mfd.ru
Omeros Achieves Commercial Milestone with First Approved Drug Launch - AD HOC NEWS
Macro Review: What is the long term forecast for Omeros Corporation stockStock Surge & Community Shared Stock Ideas - baoquankhu1.vn
Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions - Yahoo Finance
Omeros wins FDA nod for transplant therapy - MSN
Omeros Corporation (NASDAQ:OMER) Sees Large Growth in Short Interest - MarketBeat
EV Market: Is Omeros Corporation gaining market shareTrade Entry Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
Omeros higher after first commercial sales of transplant therapy - MSN
Is Omeros Corporation gaining market shareJuly 2025 Gainers & Safe Entry Momentum Stock Tips - mfd.ru
Omeros begins commercial distribution of TA-TMA treatment Yartemlea By Investing.com - Investing.com Australia
Big Money Moves: What is the implied volatility of Air Products and Chemicals IncWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn
Omeros Shares Rise After Starting Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Rises on First Shipments of Yartemlea - GuruFocus
Omeros wins first commercial sales of Yartemlea (OMER:NASDAQ) - Seeking Alpha
OMER: D. Boral Capital Maintains Buy Rating with $36 Price Targe - GuruFocus
Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital - MarketBeat
Omeros stock rises as first commercial YARTEMLEA shipments begin By Investing.com - Investing.com Canada
Omeros stock rises as first commercial YARTEMLEA shipments begin - Investing.com
Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA - GuruFocus
Omeros announces first commercial sales of Yartemlea - TipRanks
Omeros begins commercial distribution of TA-TMA treatment Yartemlea - Investing.com
Omeros Announces First Commercial Sales of YARTEMLEA® - Yahoo Finance
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Portfolio Update: Can Omeros Corporation maintain sales growthJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Growth Value: Should you buy the dip on Omeros CorporationQuarterly Growth Report & Fast Gain Stock Tips - baoquankhu1.vn
Omeros Shares Face Headwinds Amid Mixed Signals - AD HOC NEWS
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
Omeros (NASDAQ:OMER) Shares Down 5.8% Following Insider Selling - MarketBeat
Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares - MarketBeat
Omeros (OMER) Price Target Increased by 29.70% to 44.54 - Nasdaq
Omeros VP Borges sells $750k in shares By Investing.com - Investing.com Nigeria
Omeros VP Borges sells $750k in shares - Investing.com
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - msn.com
HC Wainwright Has Bearish Outlook for Omeros FY2026 Earnings - MarketBeat
Why did Omeros stock jump 5% in after-hours trading today? - MSN
Finanzdaten der Omeros Corporation-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
Omeros Corporation-Aktie (OMER) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Borges David J. | VP, Finance & CAO |
Jan 12 '26 |
Sale |
12.72 |
30,000 |
381,600 |
0 |
| Borges David J. | VP, Finance & CAO |
Jan 13 '26 |
Sale |
12.31 |
30,000 |
369,315 |
0 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):